Drugs / ERAS-801
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07089641 | Jul 2025 → Jul 2027 expected | IDH-wildtype glioblastoma, gliosarcoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06934889 | Apr 2025 → Apr 2028 expected | gliosarcoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05222802 | Feb 2022 → Aug 2025 overdue | glioblastoma | Katmai Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERAS-801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05222802 ↗ |
| Action | Inhibit | “EGFR/ERBB1 Inhibitor” NCT05222802 ↗ |
| Modality | Small molecule | — CHEMBL6068579 ↗ |
| Route | Oral | “Administered orally” NCT05222802 ↗ |
| Target | EGFR | “EGFR/ERBB1 Inhibitor” NCT05222802 ↗ |